Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEGARELIX ACETATE vs ZEGALOGUE (AUTOINJECTOR)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively and reversibly binds to Gn RH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.
Zegalogue (dasiglucagon) is a glucagon analog that binds to glucagon receptors, activating adenylate cyclase and increasing c AMP levels, which promotes glycogenolysis and gluconeogenesis in the liver, thereby raising blood glucose levels.
Treatment of advanced prostate cancer
Treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus aged 6 years and older,Off-label: Not specified
Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.
0.25 mg intramuscularly (IM) as a single dose into the anterolateral thigh, repeated once after 15 minutes if necessary.
Terminal elimination half-life is approximately 43-73 days after subcutaneous administration, reflecting slow release from the depot formulation.
50–65 minutes (terminal elimination half-life).
Hepatic via hydrolysis of the acetate ester; no significant CYP450 involvement.
Primarily metabolized via proteolytic degradation into small peptides and amino acids; not metabolized by CYP450 enzymes.
Renal elimination accounts for approximately 20-30% of the dose as unchanged drug; fecal elimination accounts for 70-80% primarily as metabolites.
Primarily hepatic metabolism followed by biliary and fecal excretion, with negligible renal elimination (<2%).
Approximately 90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Negligible (<5%); not significantly bound to plasma proteins.
Approximately 1 L/kg, indicating extensive distribution into tissues.
0.3–0.5 L/kg, indicating distribution primarily in extracellular fluid.
Subcutaneous: approximately 100% for the depot formulation; not available orally due to peptide degradation.
100% after intramuscular injection (autoinjector).
No dose adjustment required for GFR ≥15 m L/min. Insufficient data for GFR <15 m L/min or dialysis; use caution.
No dosage adjustment required for renal impairment.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C).
No dosage adjustment required for hepatic impairment.
Safety and efficacy not established in pediatric patients; no recommended dosing.
Weight-based dosing: 0.01 mg/kg IM (maximum 0.25 mg) into the anterolateral thigh, repeated once after 15 minutes if necessary.
No specific dose adjustment required; similar efficacy and safety observed in elderly patients (≥65 years) compared to younger adults.
No specific adjustment required; monitor for adverse effects due to potential comorbidities.
None
None
Hypersensitivity reactions including anaphylaxis and angioedema,QT interval prolongation,Laboratory test interference with gonadotropin and gonadal steroid assays,Injection site reactions including pain and erythema,Bone density loss,Hyperglycemia and increased risk of diabetes
Risk of hypoglycemia due to overdose or inadequate response,Risk of nausea and vomiting,Risk of hypersensitivity reactions including anaphylaxis,Risk of hyperglycemia in patients with pheochromocytoma or insulinoma
Hypersensitivity to degarelix or any component of the formulation,Pregnancy (potential fetal harm)
Known hypersensitivity to dasiglucagon or any component of the formulation,Pheochromocytoma (risk of hypertensive crisis),Insulinoma (risk of hypoglycemia)
No specific food interactions have been identified. Degarelix is administered parenterally and does not interact with dietary components. Avoid grapefruit juice if concurrent QT-prolonging drugs are used, but not a direct interaction with degarelix.
No specific food interactions. However, after successful treatment, patients should consume fast-acting carbohydrates to stabilize blood glucose levels and prevent recurrent hypoglycemia.
Category X: Contraindicated in pregnancy. First trimester: Risk of spontaneous abortion and congenital anomalies due to hormonal disruption. Second and third trimesters: Potential for fetal androgen deprivation leading to ambiguous genitalia in male fetuses.
Zegalogue (dasiglucagon) is a glucagon analog; no adequate human studies exist. In animal reproduction studies, no evidence of fetal harm was observed at doses up to 600 times the MRHD. Risk cannot be ruled out; use only if clearly needed. First trimester: limited data; theoretical risk of hyperglycemia-related effects if maternal hypoglycemia not corrected. Second and third trimesters: same as first; no known teratogenicity.
No data available on excretion in human milk; potential for serious adverse effects in nursing infants; discontinue breastfeeding or discontinue drug.
No data on dasiglucagon in human milk; excretion unknown. Glucagon is a peptide with low oral bioavailability; unlikely to be absorbed by infant. M/P ratio not available. Consider risk/benefit; monitor infant for hypoglycemia.
No dose adjustments are applicable as degarelix is contraindicated in pregnancy; therapy must be discontinued if pregnancy occurs.
No pharmacokinetic data in pregnancy; dose adjustment not recommended based on current evidence. Administer 0.6 mg as single subcutaneous dose regardless of gestational age. Monitor for recurrence of hypoglycemia; repeat dosing may be considered if needed.
Degarelix acetate is a Gn RH antagonist used for advanced prostate cancer. It provides rapid testosterone suppression without the initial testosterone surge seen with Gn RH agonists. Monitor serum testosterone and PSA levels; castrate levels (<50 ng/d L) typically achieved within 3 days. Injection site reactions are common; rotate injection sites (abdomen, thigh, buttock). Avoid in patients with known QT prolongation or concurrent QT-prolonging drugs. Contraindicated in women and children.
Zegalogue (dasiglucagon) is a glucagon analog indicated for severe hypoglycemia in diabetes patients aged 6 years and older. It is administered via autoinjector into the lower abdomen, outer thigh, or outer upper arm. Unlike reconstituted glucagon, it is stable in liquid form, allowing for rapid administration without reconstitution. Onset of action is within 10-15 minutes. Patients may experience nausea and vomiting; risk can be reduced by lying patient on side to prevent aspiration. Ensure patient has received carbohydrate intake once conscious to prevent recurrent hypoglycemia.
Degarelix is given as a subcutaneous injection by a healthcare provider every month (or every 2 months for maintenance dose) to treat advanced prostate cancer.,Do not miss scheduled injections because consistent dosing is needed to keep testosterone levels low.,Common side effects include injection site pain, redness, or swelling; hot flashes; increased liver enzymes; and weight gain.,Report signs of allergic reaction (rash, itching, difficulty breathing) or prolonged QT interval (fainting, palpitations) to your doctor immediately.,Degarelix may cause bone thinning; discuss calcium and vitamin D supplementation with your doctor.,This drug can cause harm to a fetus; not for use in women or children.
Use only for severe hypoglycemia where the patient is unable to take oral carbohydrates.,Inject into the lower abdomen, outer thigh, or outer upper arm through clothing if necessary.,Do not use if the solution is discolored or contains particles.,After injection, call emergency medical services immediately.,Turn patient on their side to prevent choking if vomiting occurs.,Once conscious, give fast-acting sugar (e.g., fruit juice, glucose tablets) to prevent recurrence.,Store at room temperature; do not freeze or expose to heat above 30°C (86°F).,Check expiration date before use.
"Asenapine, a second-generation antipsychotic, is associated with dose-dependent QTc interval prolongation due to its inhibitory effects on cardiac potassium channels (specifically IKr). Degarelix, a GnRH antagonist used in prostate cancer, may also cause QTc prolongation, likely through hormonal suppression mechanisms. Coadministration can result in additive QTc prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with pre-existing risk factors."
"Dolasetron, a 5-HT3 receptor antagonist, is known to cause dose-dependent prolongation of the QT interval by blocking cardiac potassium channels. When coadministered with Degarelix, a GnRH receptor antagonist that also reduces testosterone levels and can induce QT prolongation via electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) or direct cardiac effects, the risk of additive QT prolongation is increased. This may lead to a higher propensity for torsade de pointes and other ventricular arrhythmias, particularly in patients with pre-existing risk factors."
"Cabazitaxel is a taxane antineoplastic agent that undergoes extensive hepatic metabolism via CYP3A4/5 and is a substrate of P-glycoprotein. Degarelix, a GnRH antagonist, has no known direct metabolic interaction with Cabazitaxel but may theoretically increase the risk of QT prolongation when combined with other drugs. However, the baseline description is vague; the interaction is not well-established and possibly refers to additive myelosuppression or cardiovascular effects from overlapping toxicities."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEGARELIX ACETATE vs ZEGALOGUE (AUTOINJECTOR), answered by our medical review team.
DEGARELIX ACETATE is a GnRH antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively and reversibly binds to Gn RH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.. ZEGALOGUE (AUTOINJECTOR) is a GnRH Antagonist that works by Zegalogue (dasiglucagon) is a glucagon analog that binds to glucagon receptors, activating adenylate cyclase and increasing c AMP levels, which promotes glycogenolysis and gluconeogenesis in the liver, thereby raising blood glucose levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEGARELIX ACETATE and ZEGALOGUE (AUTOINJECTOR) depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEGARELIX ACETATE is: Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.. The standard adult dose of ZEGALOGUE (AUTOINJECTOR) is: 0.25 mg intramuscularly (IM) as a single dose into the anterolateral thigh, repeated once after 15 minutes if necessary.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEGARELIX ACETATE and ZEGALOGUE (AUTOINJECTOR) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEGARELIX ACETATE is classified as Category C. Category X: Contraindicated in pregnancy. First trimester: Risk of spontaneous abortion and congenital anomalies due to hormonal disruption. Second and third trimesters: Potential . ZEGALOGUE (AUTOINJECTOR) is classified as Category C. Zegalogue (dasiglucagon) is a glucagon analog; no adequate human studies exist. In animal reproduction studies, no evidence of fetal harm was observed at doses up to 600 times the . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.